microRNAs and their therapeutic strategy in phase I and phase II clinical trials.
Ameya KpKumaravel KaliaperumalDurairaj SekarPublished in: Epigenomics (2024)
miRNAs play a crucial therapeutic role in diseases such as cancer, diabetes and viral infections, with around 1900 identified in the human genome. Some have progressed to clinical trials, and miRNA mimics and miRNA inhibitors are pivotal therapeutic molecules undergoing evaluation. The review delves into various miRNA-associated clinical trials, emphasizing their precision in targeting specific genes, modulating disease pathways and diagnostic potential. This underscores the importance of miRNA therapy, foreseeing innovations in precision medicine techniques for diverse diseases. The future envisions improved delivery systems addressing challenges like immunogenicity and digestion, while a comprehensive miRNA-based omics database could guide the development of tailored antisense miRNAs, further advancing precision medicine strategies.
Keyphrases
- clinical trial
- phase ii
- open label
- type diabetes
- phase iii
- double blind
- cardiovascular disease
- endothelial cells
- genome wide
- papillary thyroid
- sars cov
- squamous cell carcinoma
- emergency department
- randomized controlled trial
- dna methylation
- squamous cell
- skeletal muscle
- adipose tissue
- insulin resistance
- transcription factor
- young adults
- bone marrow
- adverse drug
- childhood cancer